Business Wire

French Authorities Approve National Reimbursement of ORKAMBI (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis

Share

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the French Authorities (Comité économique des produits de santé, or CEPS) have approved national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) for people ages two and older with cystic fibrosis (CF) who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

ORKAMBI will be available for all eligible patients once the agreement has been published in the French Official Journal.

In France, ORKAMBI has been available to eligible patients ages 12 and older since December 2015 through a Temporary Use Authorization (Autorisations Temporaires d’Utilisation, or ATU) and a post-ATU interim access program. In addition to providing reimbursement for patients ages 12 and older, today’s agreement also enables people ages 2 to 11 years to access ORKAMBI in France for the first time. All those who are currently prescribed ORKAMBI through the ATU will now receive it through this new agreement.

“With today’s announcement, eligible patients across France can receive ORKAMBI through a national reimbursement agreement. Importantly, children with cystic fibrosis as young as two years of age with two copies of the F508del mutation will now benefit from this precision medicine,” said Ludovic Fenaux, Senior Vice President, Vertex International. “We thank the French Authorities for their engagement and commitment that has resulted in an agreement to provide sustainable access to ORKAMBI for all eligible patients.”

Vertex’s CF medicines are reimbursed in 21 countries around the world, including recent agreements in Australia, England and Spain.

About Cystic Fibrosis
Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.

About ORKAMBI® (lumacaftor/ivacaftor) and the F508del mutation
In people with two copies of the F508del mutation, the CFTR protein is not processed and trafficked normally within the cell, resulting in little-to-no CFTR protein at the cell surface. Patients with two copies of the F508del mutation are easily identified by a simple genetic test.

Lumacaftor/ivacaftor is a combination of lumacaftor, which is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del-CFTR protein, and ivacaftor, which is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has four approved medicines in the U.S. and three approved medicines in Europe that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney disease. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes.

Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements by Mr. Fenaux in the fourth paragraph of this press release and statements regarding our expectations for (i) the availability of ORKAMBI, and (ii) patients’ eligibility for and access to ORKAMBI. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company’s beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under Risk Factors in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Contact information

Vertex Pharmaceuticals Incorporated
Investors:
InvestorInfo@vrtx.com
or
617-961-7163

Media:
mediainfo@vrtx.com
or
International: +44 20 3204 5275
French: +33178421006
or
U.S.: 617-341-6992

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Western Union and France’s La Banque Postale Expand Global Digital Payments28.1.2020 13:59:00 EETPress release

La Banque Postale, the banking subsidiary of France’s postal services’ operator, La Poste Group and one of France’s major banking networks with 10.3 million active customers today announced - as payment agent of Western Union - the expansion of global digital payment services, powered by Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement and payments. The integration of Western Union’s global cross-border, cross-currency digital money movement platform within La Banque Postale’s mobile app and website will enable more than seven million online registered La Banque Postale customers to access Western Union’s international payment services and experience. La Banque Postale’s customers have the choice to fund their payments within the app or website using bank card and pay-out at Western Union’s Global Retail and Wallet Network. Western Union’s cross-border, cross-currency money movement platform – including global settlement capabilities, network, complianc

B2Broker Secures its Position as a PoP Liquidity Provider with Devexperts dxTrade28.1.2020 13:13:00 EETPress release

B2Broker, a leading liquidity and technology provider of solutions to the Forex and crypto industry, has signed an agreement with Devexperts, a financial software developer, to license their dxTrade platform. dxTrade is a multi-asset trading solution for brokers which, unlike other existing OTC trading platforms, supports the entire spectrum of assets. This feature will allow B2Broker to become the leading Prime of Prime liquidity provider in the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005354/en/ B2Broker Secures its Position as a PoP Liquidity Provider with Devexperts dxTrade (Photo: Business Wire) B2Broker’s pool of trading platforms currently includes OneZero Hub, PrimeXM xCore, several MT4 and MT5 trading platforms, together with B2Trader (the company’s own Matching Engine platform). With the addition of dxTrade, clients will be able to gain quick and easy access to one of the deepest liquidity poo

ADVA to play key role in OPENQKD project pioneering market-ready quantum-safe communications28.1.2020 11:00:00 EETPress release

ADVA (FSE: ADV) today announced that its FSP 3000 and FSP 150 platforms will play a pivotal role in the OPENQKD project. Leveraging its ConnectGuard™ technology, ADVA will provide optical and Ethernet encryptors as well as open line systems for multiple testbed locations. Funded by the European Commission, OPENQKD will create and trial a secure communication network across Europe based on quantum key distribution (QKD). The aim of the initiative is to accelerate the commercial adoption of QKD technology and to promote interoperability through an ecosystem of 38 partners, including academic institutions, network operators, and manufacturers of network and QKD equipment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005034/en/ ADVA's ConnectGuard™ technology is at the forefront of the OPENQKD project (Photo: Business Wire) “By bringing our technology and expertise to the OPENQKD project, we’re helping to address vital s

Lung Cancer Study Shows Barriers in Patient Access to Care in Europe28.1.2020 10:00:00 EETPress release

MSD, tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK), today presents preliminary results from a study carried out by The Economist Intelligence Unit (The EIU) on lung cancer, which show a fragmented policy approach across Europe. The study underlines that awareness needs to be addressed on multiple fronts to fight the stigma associated with this disease and to ensure patients receive timely access to the best possible care. The data were presented days before the European Commission’s official launch of the stakeholders’ consultation on Europe’s Beating Cancer Plan. “There is no room for complacency in lung cancer; 1 out of 5 of all cancer deaths in Europe is caused by lung cancer and it kills as many Europeans as breast, colon and prostate cancer combined. The study uncovers actionable solutions to empower countries and their health systems to better manage lung cancer, and ultimately, improve the lives of people living with a diagnosis of this treatable disease,” co

Teijin to Establish Teijin Automotive Center Europe to Expand Conceptual, Designing, Prototype and Evaluation Capabilities28.1.2020 04:31:00 EETPress release

Teijin Limited announced today that it would establish Teijin Automotive Center Europe GmbH (TACE) in Wuppertal, Germany in February as a new base for technical functions within the company’s automotive composite business. The company will handle concept, designing, prototyping, evaluations, marketing and technical research for next-generation automotive components, utilizing the Teijin Group’s capabilities to provide multi-material solutions for next-generation vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005758/en/ Envisioned demonstration and CAE experiments to be performed at TACE (Photo: Business Wire) TACE will enable Teijin to strengthen and advance its solution capabilities by establishing a strong platform for collaboration within the Teijin Group’s European automotive composite bases. It is expected to speed up concept, designing, prototyping and the evaluation of technological proposals developed

Rare Disease CDKL5 Deficiency Disorder Granted WHO Disease Classification27.1.2020 21:32:00 EETPress release

The rare genetic disease CDKL5 Deficiency Disorder (CDD) has been designated with a new disease code in the International Classification of Diseases (ICD), the medical classification list from the World Health Organization (WHO). The CDKL5 Deficiency Disorder diagnostic code will be incorporated in the October 1, 2020 classification revision. The medical classification, currently in its tenth revision (ICD-10), uses a list of alphanumeric codes to document a person’s medical condition. For example, a person with migraine headaches will receive the G43 code, and a person with type 2 diabetes the E11 code. These codes are then used for clinical research and care, and increasingly also for health insurance billing and reimbursement. According to the WHO, about 70% of the world’s health expenditures are allocated using ICD codes for reimbursement and resource allocation. There are many medical conditions that do not have a code in the international medical classification, and these disease

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom